Nimegel (Nimesulide)

Nimesulide preferentially inhibits the cyclooxygenase‑2 (COX‑2) enzyme, which reduces the synthesis of prostaglandins that mediate inflammation, pain and fever. By lowering prostaglandin levels locally in the skin and underlying tissues, the drug diminishes inflammatory signaling and provides analgesia without substantial systemic exposure.

The specific dose and frequency of Nimegel are determined by the prescribing healthcare professional based on the severity of the condition, the size of the treatment area and patient factors. The prescriber will provide written instructions on how much gel to apply and how often.

Safety data for topical nimesulide in pregnancy and lactation are limited. Generally, use is avoided unless the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Nimegel. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nimegel contains nimesulide, which has a higher selectivity for COX‑2 compared with some older topical NSAIDs such as diclofenac. This may translate into a lower risk of local skin irritation for some patients, while providing comparable analgesic efficacy. Choice of product should consider individual tolerance, cost and physician preference.

Store Nimegel at room temperature, preferably below 25 °C, in its original packaging. Protect the container from moisture, direct sunlight and extreme temperatures. Keep the tube tightly closed when not in use and keep it out of reach of children.

Apply a thin layer of the gel to the affected skin area, typically 2–4 g depending on the size of the region, and gently massage until fully absorbed. Use the product as directed by the prescriber, usually 2–3 times daily, and avoid covering the area with occlusive dressings unless advised.

Although applied locally, Nimegel can cause severe adverse reactions such as allergic skin reactions (e.g., Stevens‑Johnson syndrome), systemic hypersensitivity, hepatic toxicity, or severe skin necrosis. Patients should discontinue use and seek immediate medical attention if they experience widespread rash, blistering, jaundice, or unexplained fatigue.

Nimegel should not be used by individuals with known hypersensitivity to nimesulide or any component of the formulation, on broken or infected skin, or by patients with severe liver disease without medical supervision. Pregnant women, breastfeeding mothers and children should avoid use unless explicitly prescribed by a qualified clinician.